share_log

ArriVent BioPharma FY23 EPS $(32.38) Vs $(28.90) YoY

ArriVent BioPharma FY23 EPS $(32.38) Vs $(28.90) YoY

ArriVent BioPharma 23財年每股收益爲32.38美元，同比增長28.90美元
Benzinga ·  03/29 04:38

Fiscal Year 2023 Financial Results

2023 財年財務業績

  • Research and development expenses were $64.9 million and $30.4 million for the years ended December 31, 2023 and 2022, respectively. The increase in expense was primarily due to increased clinical spending on trials related to furmonertinib.
  • General and administrative expenses were $9.7 million and $6.5 million for the years ended December 31, 2023 and 2022, respectively. The increase was primarily due to increased external costs related to preparing for and operating as a public company, as well as increased personnel costs to support these activities.
  • Net loss was $69.3 million and $37.0 million for the years ended December 31, 2023 and 2022, respectively.
    • As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $150.4 million, which, with the proceeds from our IPO in January 2024, is expected to fund operations into 2026.
  • 截至2023年12月31日和2022年12月31日止年度的研發費用分別爲6,490萬美元和3,040萬美元。支出的增加主要是由於與弗莫那替尼相關的試驗的臨床支出增加。
  • 截至2023年12月31日和2022年12月31日止年度，一般和管理費用分別爲970萬美元和650萬美元。增長的主要原因是與上市公司籌備和運營相關的外部成本增加，以及支持這些活動的人事成本增加。
  • 截至2023年12月31日和2022年12月31日止年度的淨虧損分別爲6,930萬美元和3,700萬美元。
    • 截至2023年12月31日，該公司的現金、現金等價物和有價證券爲1.504億美元，加上我們在2024年1月首次公開募股的收益，預計將爲2026年的運營提供資金。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論